Search Results

Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”

Lexaria Bioscience Corp. which will evaluate various DehydraTECH-GLP-1 formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces it has hired a contract research organization to perform the Company’s human pilot study #3, which will evaluate a dual action GLP-1 + GIP.

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.

NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?”.

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.